Precision targeting of CCNE1-amplified tumors—lessons from BLU-222 and beyond

High-grade serous ovarian cancer (HGSOC) and aggressive forms of endometrial carcinoma remain among the most difficult gynecologic cancers to treat (1,2). Despite advances in surgery, chemotherapy, and the introduction of poly(ADP-ribose) polymerase (PARP) inhibitors, resistance and relapse remain the rule rather than the exception. In particular, tumors harboring CCNE1 amplification represent a high-risk subset characterized by genomic instability, poor chemotherapy response, and limited therapeutic options (3). These tumors frequently resist DNA-damaging chemotherapy and are not typically responsive to PARP inhibition, leaving patients with few alternatives.

Efforts to exploit CCNE1 amplification for treatment benefits have historically struggled. Cyclin E1 itself is not an enzyme and therefore is not directly targetable. However, its oncogenic activity depends on binding to and activating cyclin-dependent kinase 2 (CDK2), a critical regulator of the G1/S transition. This aspect made CDK2 an attractive therapeutic target, provided that selective and tolerable inhibitors can be developed. To address this, a new generation of selective CDK2 inhibitors, such as PF-07104091, INX-315 and BLU-222 among others have now entered clinical trials, addressing the limits of earlier broad cyclin-dependent kinase (CDK) inhibitors (4-7).

In this context, House et al. (6) present a comprehensive preclinical profile of BLU-222, a potent and selective CDK2 inhibitor, across a variety of CCNE1-driven cancer models. Their work demonstrates the efficacy of BLU-222 in CCNE1-amplified ovarian and endometrial models, introduces refined biomarkers for patient selection, and proposes rational therapeutic combinations. This study marks an important step in moving CDK2 inhibition from concept to clinical application.

A critical contribution of the House et al. study lies in the refinement of biomarkers for predicting CDK2 inhibitor sensitivity. The authors demonstrate that elevated CCNE1 mRNA expression alone is insufficient to stratify responders, highlighting the limitations of relying on single-gene markers. Instead, they identify two additional determinants of sensitivity: intact retinoblastoma protein (Rb) function and cyclin-dependent kinase inhibitor 2A protein (p16) expression. For instance, in p16-low cells that harbor active cyclin-dependent kinases 4 and 6 (CDK4/6), co-targeting CDK2 and CDK4/6 restored BLU-222 sensitivity. In contrast, in p16-high cells adding a CDK4/6 inhibitor provided no additional benefit over BLU-222 alone. Moreover, BLU-222 acted as a chemosensitizer in CCNE1-high, Rb-intact tumors. When paired with platinum or taxane chemotherapy, it converted static disease to regression, and non-response to stasis. Given that platinum/taxane resistance is a hallmark of CCNE1-aberrant tumors and drives poor outcomes with few options available for reversing it, this finding is especially compelling (8). If translated clinically, BLU-222 could improve patient outcomes by restoring effectiveness of standard treatments rather than replacing them.

When integrated with CCNE1 amplification, intact Rb and high-p16 define a biomarker triad that more accurately predicts the efficacy of BLU-222 than CCNE1 status alone. This biomarker framework has important translational implications. Restricting patient selection to CCNE1-amplified tumors captures a high-risk subgroup but does not adequately discriminate true responders from non-responders. By incorporating Rb and p16 status, House et al. sharpen patient stratification, delineating a subset of CCNE1-high, Rb-intact, p16-high tumors that most likely will benefit from CDK2 inhibition. Conversely, tumors lacking Rb or exhibiting low p16 expression are predicted to resist CDK2 blockade, suggesting that these cases may require alternative therapeutic strategies.

Such biomarker-driven selection strengthens precision oncology paradigms. For example, the clinical success of CDK4/6 inhibitors in breast cancer relies on intact Rb function, which is necessary for pathway inhibition to translate into tumor arrest (9). Similarly, excluding patients unlikely to respond to BLU-222 on the basis of biomarker status could maximize therapeutic efficacy while minimizing unnecessary exposure and toxicity.

Parallel efforts have been exploring alternative vulnerabilities in CCNE1-aberrant tumors. In a recent Oncogene study, Xi et al. showed that cyclin E1 overexpression sensitizes ovarian cancer cells to inhibition of the G2/M checkpoint kinases WEE1 G2 checkpoint kinase (WEE1) and polo-like kinase 1 (PLK1) (10). By exploiting the replication stress inherent to CCNE1-driven tumors, checkpoint inhibition induces catastrophic DNA damage and apoptosis. Together, these studies highlight complementary but mechanistically distinct strategies for treating CCNE1-amplified tumors: direct disruption of the cyclin E1-CDK2 axis (House et al.) versus synthetic lethality through checkpoint inhibition (Xi et al.). The preclinical characterization of BLU-222 provides a strong translational rationale for CDK2 inhibition in CCNE1-amplified ovarian and endometrial cancers. By refining biomarkers to include Rb and p16 status, and by demonstrating synergy with both CDK4/6 inhibitors and chemotherapy, the authors lay the foundation for biomarker-driven clinical trials that could finally address a treatment-resistant subgroup. On the other hand, the work by Xi et al. complements this advance, highlighting that cyclin E1 overexpression also sensitizes tumors to checkpoint inhibition.

Both approaches have their strengths. CDK2 inhibition is more specific to the driver oncogene and benefits from biomarker refinement, while checkpoint inhibition may apply more broadly to cyclin E1-overexpressing tumors and leverages drugs already in the clinic. The strategies are not mutually exclusive: in fact, they could be complementary, either in stratified patient groups or in rational combinations. From a translational standpoint, the BLU-222 approach may hold an advantage in precision and therapeutic index, particularly given its potential to restore chemotherapy sensitivity. Yet, checkpoint inhibition remains attractive for patients whose tumors do not meet the refined biomarker profile for CDK2 inhibition.

Despite encouraging preclinical data, both CDK2 and checkpoint inhibition strategies face significant translational challenges that must be addressed before they can achieve clinical impact. CCNE1-amplified or cyclin E1-high tumors comprise only a fraction of ovarian and endometrial cancers, making patient accrual difficult and likely requiring multicenter collaboration and adaptive trial designs to ensure adequately powered studies. Equally critical is the development and validation of robust biomarker assays: accurate detection of CCNE1 amplification or overexpression, together with assessment of Rb and p16 status, will be essential for reliable patient stratification. Drug resistance is another anticipated barrier, as experience with CDK4/6 inhibitors has shown that tumor cells can escape pathway inhibition through Rb loss, the activation of compensatory CDK complexes, or the rewire of checkpoint controls; similar mechanisms are likely to emerge under CDK2 or checkpoint blockade, underscoring the need for preclinical modeling to guide rational combination strategies (11,12). Finally, tolerability will be a decisive factor in translation. Although BLU-222 demonstrates high selectivity for CDK2, inhibition of this kinase in normal proliferating tissues could produce clinical toxicity due to its central roles in cell-cycle regulation. Defining therapeutic windows that maximize efficacy while minimizing systemic toxicity will therefore be essential for the clinical success of these approaches.

In conclusion, the work by House et al. highlights both the potential and challenges in targeting CCNE1-driven disease. By putting CDK2 inhibition in a perspective that goes beyond CCNE1 alone, the study provides a path towards meaningful patient selection and rational combinations. Whether BLU-222 ultimately improves outcomes will depend on rigorous clinical validation, clinical trial design, and standardized diagnostics. Still, this study makes an important point by showing that even the most treatment-resistant subgroups can be targeted when patient selection and combinations are done right.

If planned properly, targeting cyclin E1 addiction - whether through CDK2 inhibition, checkpoint blockade, or combinations thereof - may finally deliver meaningful options for patients with CCNE1-driven gynecologic cancers.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the Editorial Office, Translational Cancer Research. The article did not undergo external peer review.

Funding: This work was supported by the Research Council of Finland (Profi6 #336449, #333583, #360437 to D.U.), the Sigrid Jusélius Foundation (to D.U.), and the Cancer Foundation Finland (to D.U.).

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-2105/coif). D.U. reports that this work was supported by the Research Council of Finland (Profi6 #336449, #333583, #360437, the Sigrid Jusélius Foundation, and the Cancer Foundation Finland. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Yang L, Xie HJ, Li YY, et al. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer Oncol Rep 2022;47:82. (Review). [Crossref] [PubMed]
2. Rubinstein M, Shen S, Monk BJ, et al. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. Gynecol Oncol 2022;167:540-6. [Crossref] [PubMed]
3. Gorski JW, Ueland FR, Kolesar JM. CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. Diagnostics (Basel) 2020;10:279. [Crossref] [PubMed]
4. Yap TA, Elhaddad AM, Grisham RN, et al. First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer. J Clin Oncol 2023;41:3010. [Crossref]
5. Dietrich C, Trub A, Ahn A, et al. INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer Discov 2024;14:446-67. [Crossref] [PubMed]
6. House NC, Brown VE, Chen M, et al. Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors. Cancer Res 2025;85:1297-309. [Crossref] [PubMed]
7. Zhang M, Zhang L, Hei R, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res 2021;11:1913-35. [PubMed]
8. Wiedemeyer WR, Beach JA, Karlan BY. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. Front Oncol 2014;4:34. [Crossref] [PubMed]
9. Shanabag A, Armand J, Son E, et al. Targeting CDK4/6 in breast cancer. Exp Mol Med 2025;57:312-22. [Crossref] [PubMed]
10. Xi Q, Kunita A, Ogawa M, et al. Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition. Oncogene 2025;44:1375-86. [Crossref] [PubMed]
11. Palafox M, Monserrat L, Bellet M, et al. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer. Nat Commun 2022;13:5258. [Crossref] [PubMed]
12. Ogata R, Kishino E, Saitoh W, et al. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells. Breast Cancer 2021;28:206-15. [Crossref] [PubMed]